<DOC>
	<DOCNO>NCT00538434</DOCNO>
	<brief_summary>This trial study three dos reslizumab versus placebo child eosinophilic esophagitis ( EE ) . The objective trial study effectiveness reslizumab improve clinical sign symptom reduce esophageal eosinophil well assess safety profile compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Study Reslizumab Treat Eosinophilic Esophagitis Subjects Aged 5 18 Years</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>write informed consent obtain male female patient age 5 18 year time screen nonchildbearing potential , childbearing potential willing use specific barrier method outline protocol confirm active EE ( Screening within six week prior Baseline Visit ) define esophageal mucosal eosinophils great equal 24 per high power field ( hpf ; 400X magnification ) within week prior dosing , patient one follow symptom moderate ( bad ) severity : vomiting , regurgitation ( acid taste feel material movement upward ) , abdominal , chest pain/heartburn ( burn pain behind sternum ) , difficulty swallow therapeutic dose proton pump inhibitor ( PPIs ; without histamine H2 receptor antagonist ) least four week without resolution symptom , negative pH probe ( without fail course PPIs ) another disorder cause esophageal eosinophilia ( e.g. , hypereosinophilic syndrome [ HES ] , Churg Strauss vasculitis , eosinophilic gastroenteritis [ EG ] , parasitic infection ) history abnormal gastric duodenal biopsy document gastrointestinal [ GI ] disorder ( e.g. , celiac disease , Crohn 's disease Helicobacter pylori infection ) history follow GI surgery : fundoplication , gastric surgery surgery intestinal atresia use systemic immunosuppressive immunomodulating agent ( antiimmunoglobulin E [ IgE ] monoclinal antibody [ mAb ] , methotrexate , cyclosporin , interferon alpha [ Î± ] , anti tumor necrosis factor [ TNF ] mAb ) within six month prior study entry receive attenuated live attenuate vaccine ( e.g. , measles , mumps , rubella [ MMR ] , bacillus CalmetteGuerin [ BCG ] , varicella , FluMist polio ) within three month prior study entry use swallow inhaled corticosteroid treatment EE within one month prior study entry . Note : Inhaled nasal corticosteroid treatment asthma allergy , respectively , permit provide dose remain study stricture endoscopy prevents passage endoscope participation investigational drug device study within 30 day prior study entry female subject pregnant nursing concurrent infection disease may preclude assessment EE concurrent immunodeficiency ( human immunodeficiency [ HIV ] , acquire immunodeficiency syndrome [ AIDS ] congenital immunodeficiency )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Eosinophilic Esophagitis</keyword>
	<keyword>GERD</keyword>
	<keyword>EE</keyword>
	<keyword>Reslizumab</keyword>
	<keyword>IL-5</keyword>
	<keyword>Interleukin-5</keyword>
	<keyword>Cinquil</keyword>
</DOC>